ArticleJournal of global health2026
Epidemic trends and characteristics of notifiable infectious diseases in mainland China during the COVID-19: a nationwide surveillance study, 2020-2024.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The implementation of COVID-19 control and prevention measures has significantly influenced the incidence rates of multiple notifiable infectious diseases. We aimed to investigate the epidemiological trends of notifiable infectious diseases in mainland China from 2020 to 2024, a period spanning both stringent interventions and their subsequent relaxation. Methods: We systematically analysed surveillance data from the National Center for Disease Control and Prevention (2020-2024). We excluded COVID-19, monkeypox, and neonatal tetanus to ensure methodological consistency and comparability. We classified the diseases into Class A, B, and C notifiable infectious diseases and further grouped them by transmission routes: intestinal, respiratory, sexually transmitted and blood-borne, vector-borne/zoonotic, and others. We focused on incidence rates, mortality rates, seasonal patterns, and trends to inform future prevention and control strategies. Results: Between 2020 and 2024, mainland China recorded 38 notifiable infectious diseases (excluding COVID-19, monkeypox, and neonatal tetanus). The average incidence rate was 734.8945/100 000, showing an upward trend. Class A notifiable infectious diseases were extremely rare, Class B encompassed 25 types and showed a rising trend with minimal seasonal variation, and Class C included 11 types. Class C notifiable infectious diseases incidence remained relatively low from 2020 to 2022, but rose sharply in 2023 after the relaxation of COVID-19 restrictions, maintaining elevated levels in 2024, with pronounced winter/spring peaks observed, especially in 2023-2024. Respiratory infectious diseases (RIDs) exhibited the highest incidence, while blood-borne and sexually transmitted infectious diseases accounted for over 90.35% of the deaths. Conclusions: In mainland China, strict COVID-19 measures between 2020 and 2022 significantly reduced the incidence of RIDs. However, after COVID-19 management was downgraded and restrictions were relaxed in early 2023, these diseases resurged, demonstrating a 'suppression-rebound' effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.